I contacted the company to get some clarification on the 500 cohort validation study requested by our potential (and apparently keen) commercialisation partner. I was particularly concerned about the timeframe to do another validation study.
The Company said that it does not expect there to be an extended timeframe for the reporting of results, as the patient cohort was taken from the Fremantle Diabetes Study, a large ongoing study, which means there is no lead time in trial patient recruitment and then time-in-the-trial – the patient cohort is already readily available.
I also queried them on the impact of the new development program for PromarkerD IVD test kit and its impact/relationship on current partnering discussions. They indicated that it's completely complementary to the Company’s ongoing partnering and licensing discussions. It provides multiple commercialisation pathways for PromarkerD, and in no way impacts on the multiple, positive ongoing commercialisation discussions.
I agree with @sbarett regarding the potential for this tightly held little gem to rapidly appreciate once the ink dries on any commercialisation deal and I get the sense that it may not be too far away. The smart money is accumulating at a heavy discount as patience thins.
As always, DYOR.
PIQ Price at posting:
25.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)